The present disclosure provides a process for preparation of 3,6-dichlorocyano pyrazine, 3,6-dioxopiperizine derivatives and production of favipiravir via ammonia or amine-mediated cyclization and chlorination using POCl3 in the presence of pyridine or PCl5. [Formula] wherein in 3,6-dioxopiperazine derivatives (III), X is CN, CONH2 or COOR2′, R1, R2 and R2′ are individually selected from H, C1-C12 alkyl, COOR3 and SO2R3 wherein R3 is substituted or unsubstituted linear or branched lower alkyl.

##STR00001##

The present disclosure provides a process for preparation of 3,6-dichlorocyano pyrazine, 3,6-dioxopiperizine derivatives and production of favipiravir via ammonia or amine-mediated cyclization and chlorination using POCl3 in the presence of pyridine or PCl5. [Formula] wherein in 3,6-dioxopiperazine derivatives (III), X is CN, CONH2 or COOR2′, R1, R2 and R2′ are individually selected from H, C1-C12 alkyl, COOR3 and SO2R3 wherein R3 is substituted or unsubstituted linear or branched lower alkyl.

##STR00001##

The present invention relates to novel ACSS2 inhibitors having activity as anti-cancer therapy, treatment of alcoholism, and viral infection (e.g., CMV), composition and methods of preparation thereof, and uses thereof for treating viral infection, alcoholism, alcoholic steatohepatitis (ASH), non-alcoholic steatohepatitis (NASH), obesity/weight gain, anxiety, depression, post-traumatic stress disorder, inflammatory/autoimmune conditions and cancer, including metastatic cancer, advanced cancer, and dmg resistant cancer of various types.

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. ##STR00001##

The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer). In some embodiments, the present invention relates to compounds of formula (I): ##STR00001## or pharmaceutically acceptable salts or prodrugs thereof.

The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer). In some embodiments, the present invention relates to compounds of formula (I): ##STR00001## or pharmaceutically acceptable salts or prodrugs thereof.

Pyrazinamide (PZA) conjugates and hybrids are provided herein. The PZA conjugates are useful for treating bacterial infections. In one embodiment, the PZA conjugates are useful for treating tuberculosis.

Pyrazinamide (PZA) conjugates and hybrids are provided herein. The PZA conjugates are useful for treating bacterial infections. In one embodiment, the PZA conjugates are useful for treating tuberculosis.

The present invention relates to compounds which inhibit histone deacetylase activity and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing these compounds. The present invention also relates to methods of treating and preventing hematological cell proliferative disorders, such as multiple myeloma, by administering these compounds and pharmaceutical compositions to subjects in need thereof.